739 related articles for article (PubMed ID: 16129848)
1. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
3. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
4. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
6. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
8. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
9. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
[TBL] [Abstract][Full Text] [Related]
10. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
11. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
12. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Green DM; Breslow NE; Evans I; Moksness J; D'Angio GJ
Med Pediatr Oncol; 1996 Mar; 26(3):147-52. PubMed ID: 8544795
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
14. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
[TBL] [Abstract][Full Text] [Related]
15. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.
Spreafico F; Gamba B; Mariani L; Collini P; D'Angelo P; Pession A; Di Cataldo A; Indolfi P; Nantron M; Terenziani M; Morosi C; Radice P; Perotti D;
J Urol; 2013 Jan; 189(1):260-6. PubMed ID: 23174227
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP
Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157
[TBL] [Abstract][Full Text] [Related]
19. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.
Yeh A; Wei M; Golub SB; Yamashiro DJ; Murty VV; Tycko B
Genes Chromosomes Cancer; 2002 Oct; 35(2):156-63. PubMed ID: 12203779
[TBL] [Abstract][Full Text] [Related]
20. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children.
Loke BN; Wong MK; Tawng KD; Kuick CH; Jain S; Lian D; Wagner E; Zou Y; Ganesan V; Sim SW; Lee YT; Chin F; Chan MY; Tan AM; Teh BT; Soh SY; Chang KTE; Loh AHP
Int J Cancer; 2019 Mar; 144(6):1234-1242. PubMed ID: 30362502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
